07.25.12
GlaxoSmithKline
2Q Revenues: $10.2 billion (-7%)
2Q Earnings: $2.1 billion (+10%)
YTD Revenues: $20.7 billion (-4%)
YTD Earnings: $4.3 billion (-2%)
Comments: Pharmaceuticals sales in the quarter were down 3% to $6.9 billion, reflecting the loss of Vesicare sales following the conclusion of the co-promotion agreement in 1Q12. Seretide/Advair sales were $2.0 billion (-5%). Lamictal sales were $232 million (+10%). Avodart sales were $311 million (+1%). Vaccines sales were $1.2 billion (-8%). Hepatitis vaccine sales were $260 million (-17%). Infanrix, Pediarix sales were $283 million (+11%). Rotarix sales were $147 million (+19%).
2Q Revenues: $10.2 billion (-7%)
2Q Earnings: $2.1 billion (+10%)
YTD Revenues: $20.7 billion (-4%)
YTD Earnings: $4.3 billion (-2%)
Comments: Pharmaceuticals sales in the quarter were down 3% to $6.9 billion, reflecting the loss of Vesicare sales following the conclusion of the co-promotion agreement in 1Q12. Seretide/Advair sales were $2.0 billion (-5%). Lamictal sales were $232 million (+10%). Avodart sales were $311 million (+1%). Vaccines sales were $1.2 billion (-8%). Hepatitis vaccine sales were $260 million (-17%). Infanrix, Pediarix sales were $283 million (+11%). Rotarix sales were $147 million (+19%).